<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473355</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-0003</org_study_id>
    <nct_id>NCT01473355</nct_id>
  </id_info>
  <brief_title>Study on OsseoSpeed™ TX Narrow Implants in the Lower Jaw in a Chinese Population</brief_title>
  <official_title>An Open, Prospective, Multi-center Study to Evaluate OsseoSpeed™ TX Single Implant 3 mm Diameter in the Anterior Mandible. A 3-years Follow-up Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dentsply Sirona Implants</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dentsply Sirona Implants</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the clinical efficacy of OsseoSpeed™ TX 3mm
      diameter implant in a Chinese population by evaluation of marginal bone level alteration,
      implant stability and implant survival in the posterior mandible up to 3 years after loading.
      Hypothesis: Early loading of the 3 mm implant is a safe and predictable procedure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Survived Implants</measure>
    <time_frame>Measured at the 3 year follow-up after implant loading.</time_frame>
    <description>Implant survival rate evaluated by clinically and radiographically counting the number of implants remaining in function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Marginal Bone Level Alteration</measure>
    <time_frame>Measured at the 3 year follow-up after implant loading.</time_frame>
    <description>Marginal bone level determined from radiographs and expressed as the distance from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant. Marginal bone level expressed in millimeters at the 3 year follow-up visit compared to values obtained at delivery of permanent restoration i.e. loading (baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Stable Implants</measure>
    <time_frame>Measured at the 3 year follow-up after implant loading.</time_frame>
    <description>Implant stability evaluated clinically/manually (recorded as stable yes/no).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Periimplant Mucosa Condition - By Assessment of PPD</measure>
    <time_frame>Measured at the 3 year follow-up after implant loading.</time_frame>
    <description>Condition of the periimplant mucosa by assessment of probing pocket depth (PPD).
Change in pocket depth expressed in millimeters at the 3-year follow-up visit, compared to values obtained at delivery of permanent restoration, i.e. loading (baseline).
Negative value = increased pocket depth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Periimplant Mucosa Condition - By Assessment of BoP</measure>
    <time_frame>Measured at the 3 year follow-up after implant loading.</time_frame>
    <description>Condition of the periimplant mucosa by assessment of Bleeding on Probing (BoP). Presented as % of implants that show presence of bleeding on probing at time of the 3-year follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Plaque</measure>
    <time_frame>Measured at the 3 year follow-up after implant loading.</time_frame>
    <description>Occurence of plaque around the study implant. Presented as number of implants that show presence of plaque at time of the 3 years follow-up visit after implant loading.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Partially Edentulous Jaw</condition>
  <arm_group>
    <arm_group_label>OsseoSpeed™ TX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OsseoSpeed™ TX narrow implants (diameter 3 mm) in lengths of 11-15 mm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OsseoSpeed™ TX</intervention_name>
    <description>OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm</description>
    <arm_group_label>OsseoSpeed™ TX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Provision of informed consent

          2. Aged 20-75 years at enrolment

          3. History of edentulism in the study area of at least two months

          4. Presence of natural teeth, partial prosthesis and/or implants in the opposite jaw in
             contact with the planned crowns

          5. Deemed by the investigator to have a bone height and width suitable for 3.0 mm
             diameter study implant

          6. Deemed by the investigator as likely to present an initially stable implant situation

        Exclusion Criteria:

          1. Unlikely to be able to comply with study procedures, as judged by the investigator

          2. Uncontrolled pathologic processes in the oral cavity

          3. Known or suspected current malignancy

          4. History of radiation therapy in the head and neck region

          5. History of chemotherapy within 5 years prior to surgery

          6. Systemic or local disease or condition that could compromise post-operative healing
             and/or osseointegration, as deemed by the investigator

          7. Uncontrolled diabetes mellitus

          8. Corticosteroids or any other medication that could influence post-operative healing
             and/or osseointegration

          9. Smoking more than 10 cigarettes per day

         10. Present alcohol and/or drug abuse

         11. Involvement in the planning and conduct of the study (applies to both Astra Tech staff
             and staff at the study site)

         12. Previous enrollment in the present study

         13. Simultaneous participation in another clinical study, or participation in a clinical
             study during the last weeks prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping Gong, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sichuan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>School of Stomatology, JiLin University, Hospital of Stomatology</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 15, 2011</study_first_submitted>
  <study_first_submitted_qc>November 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <results_first_submitted>February 11, 2019</results_first_submitted>
  <results_first_submitted_qc>September 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 7, 2019</results_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Jaw, Edentulous</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OsseoSpeed™ TX</title>
          <description>OsseoSpeed™ TX narrow implant (diameter 3 mm) in lengths of 11-15 mm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OsseoSpeed™ TX</title>
          <description>OsseoSpeed™ TX narrow implants (diameter 3 mm) in lengths of 11-15 mm</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Implants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Survived Implants</title>
        <description>Implant survival rate evaluated by clinically and radiographically counting the number of implants remaining in function</description>
        <time_frame>Measured at the 3 year follow-up after implant loading.</time_frame>
        <population>All participants treated with at least one study implant.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX</title>
            <description>OsseoSpeed™ TX narrow implants (diameter 3 mm) in lengths of 11-15 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Survived Implants</title>
          <description>Implant survival rate evaluated by clinically and radiographically counting the number of implants remaining in function</description>
          <population>All participants treated with at least one study implant.</population>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Marginal Bone Level Alteration</title>
        <description>Marginal bone level determined from radiographs and expressed as the distance from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant. Marginal bone level expressed in millimeters at the 3 year follow-up visit compared to values obtained at delivery of permanent restoration i.e. loading (baseline).</description>
        <time_frame>Measured at the 3 year follow-up after implant loading.</time_frame>
        <population>39 subjects (65 implants) completed the 3-year follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 34 subjects (60 implants). Three of the radiographs were not possible to evaluate, giving an overall number of 32 subjects (57 implants) as basis for the Marginal Bone Level analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX</title>
            <description>OsseoSpeed™ TX narrow implants (diameter 3 mm) in lengths of 11-15 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Marginal Bone Level Alteration</title>
          <description>Marginal bone level determined from radiographs and expressed as the distance from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant. Marginal bone level expressed in millimeters at the 3 year follow-up visit compared to values obtained at delivery of permanent restoration i.e. loading (baseline).</description>
          <population>39 subjects (65 implants) completed the 3-year follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 34 subjects (60 implants). Three of the radiographs were not possible to evaluate, giving an overall number of 32 subjects (57 implants) as basis for the Marginal Bone Level analysis.</population>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Stable Implants</title>
        <description>Implant stability evaluated clinically/manually (recorded as stable yes/no).</description>
        <time_frame>Measured at the 3 year follow-up after implant loading.</time_frame>
        <population>39 subjects (65 implants) completed the 3-year follow-up visit. Analysis of implant stability was performed on the all patients treated population.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX</title>
            <description>OsseoSpeed™ TX narrow implants (diameter 3 mm) in lengths of 11-15 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Stable Implants</title>
          <description>Implant stability evaluated clinically/manually (recorded as stable yes/no).</description>
          <population>39 subjects (65 implants) completed the 3-year follow-up visit. Analysis of implant stability was performed on the all patients treated population.</population>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Periimplant Mucosa Condition - By Assessment of PPD</title>
        <description>Condition of the periimplant mucosa by assessment of probing pocket depth (PPD).
Change in pocket depth expressed in millimeters at the 3-year follow-up visit, compared to values obtained at delivery of permanent restoration, i.e. loading (baseline).
Negative value = increased pocket depth.</description>
        <time_frame>Measured at the 3 year follow-up after implant loading.</time_frame>
        <population>39 subjects (65 implants) completed the 3-year follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 34 subjects (60 implants) for the PPD analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX</title>
            <description>OsseoSpeed™ TX narrow implants (diameter 3 mm) in lengths of 11-15 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of the Periimplant Mucosa Condition - By Assessment of PPD</title>
          <description>Condition of the periimplant mucosa by assessment of probing pocket depth (PPD).
Change in pocket depth expressed in millimeters at the 3-year follow-up visit, compared to values obtained at delivery of permanent restoration, i.e. loading (baseline).
Negative value = increased pocket depth.</description>
          <population>39 subjects (65 implants) completed the 3-year follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 34 subjects (60 implants) for the PPD analysis.</population>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Periimplant Mucosa Condition - By Assessment of BoP</title>
        <description>Condition of the periimplant mucosa by assessment of Bleeding on Probing (BoP). Presented as % of implants that show presence of bleeding on probing at time of the 3-year follow-up visit.</description>
        <time_frame>Measured at the 3 year follow-up after implant loading.</time_frame>
        <population>39 subjects (65 implants) completed the 3-year follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 34 subjects (60 implants) for the BoP analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX</title>
            <description>OsseoSpeed™ TX narrow implants (diameter 3 mm) in lengths of 11-15 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of the Periimplant Mucosa Condition - By Assessment of BoP</title>
          <description>Condition of the periimplant mucosa by assessment of Bleeding on Probing (BoP). Presented as % of implants that show presence of bleeding on probing at time of the 3-year follow-up visit.</description>
          <population>39 subjects (65 implants) completed the 3-year follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 34 subjects (60 implants) for the BoP analysis.</population>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Plaque</title>
        <description>Occurence of plaque around the study implant. Presented as number of implants that show presence of plaque at time of the 3 years follow-up visit after implant loading.</description>
        <time_frame>Measured at the 3 year follow-up after implant loading.</time_frame>
        <population>39 subjects (65 implants) completed the 3-year follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 34 subjects (60 implants) for the plaque analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX</title>
            <description>OsseoSpeed™ TX narrow implants (diameter 3 mm) in lengths of 11-15 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Plaque</title>
          <description>Occurence of plaque around the study implant. Presented as number of implants that show presence of plaque at time of the 3 years follow-up visit after implant loading.</description>
          <population>39 subjects (65 implants) completed the 3-year follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 34 subjects (60 implants) for the plaque analysis.</population>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>OsseoSpeed™ TX</title>
          <description>OsseoSpeed™ TX narrow implants (diameter 3 mm) in lengths of 11-15 mm</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Possible ablepsia of right eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture left leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager Global Clinical Research</name_or_title>
      <organization>Dentsply Sirona Implants, Mölndal, SWEDEN</organization>
      <phone>0046313763500</phone>
      <email>ClinicalResearchMolndal@dentsplysirona.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

